Article

Study: Glucosamine and Chondroitin Supplements Show No Arthritic Benefit Over Placebo

Author(s):

Popularly sold to improve joint health, a recent Spanish study found the benefits of CS+GS supplements on par with (and in some cases outperformed by) placebos.

Rheumatology, osteoarthritis, arthritis treatment, internal medicine, joint health, primary care, supplements, glucosamine, chondroitin, rheumatologists, arthritis

Glucosamine sulfate (GS) and chondroitin sulfate (CS), often sold together in popular supplements that claim to support joint health, fared no better than placebo in a recent double-blind study. Researchers in Spain gathered 164 patients with knee osteoarthritis (KOA), and they were randomly given either a CS+GS supplement or a placebo. In some study populations, the placebo actually performed better.

"This is the first randomized controlled trial sponsored by a pharmaceutical company to evaluate the efficacy of a combination of CS and GS and that included a Data and Safety Monitoring Board, or DSMB, composed of independent experts charged with ensuring participant safety and accurate, bias-free data,” says co-author Gabriel Herrero-Beaumont in an accompanying press release.

A previous study, the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) conducted over years by the National Center for Complementary and Integrative Health (NCCAM) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, also produced mixed results for CS+GS. The study also compared celecoxib (brand name Celebrex), and after a two-year comparison, found “no treatment achieved a clinically important difference in WOMAC pain or function as compared with placebo.” WOMAC refers to the Western Ontario and McMaster Universities Arthritis Index, a commonly-used questionnaire for evaluating arthritic symptoms.

While no questions emerged as to the safety of CS+GS supplements, the studies maintained that “CS+GS failed to demonstrate superiority over placebo in reducing pain and function impairment in patients with symptomatic KOA at 6 months,” suggesting that “Further research may contribute to fully elucidate the suitability of CS+GS combination as therapy in OA.”

The study took place over the course of six months. Like GAIT, it involved daily dosages of 1500mg GS and 1200mg CS, levels comparable to those suggested in popular over-the-counter supplements like Osteo Bi-Flex.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.